ArticleScientific reports2017
Identification of a novel NAMPT inhibitor by CRISPR/Cas9 chemogenomic profiling in mammalian cells.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Arrayed CRISPR libraries for the genome-wide activation, deletion and silencing of human protein-coding genes.Nature biomedical engineering · 2025Article
- Review
- Small Molecule Regulators Targeting NADCurrent medicinal chemistry · 2022Article
- From Rate-Limiting Enzyme to Therapeutic Target: The Promise of NAMPT in Neurodegenerative Diseases.Frontiers in pharmacology · 2022Review
- Common computational tools for analyzing CRISPR screens.Emerging topics in life sciences · 2021Review
- Genome-wide CRISPR-Cas9 screens identify mechanisms of BET bromodomain inhibitor sensitivity.iScience · 2021Article
- Genome-wide CRISPR screen identifies protein pathways modulating tau protein levels in neurons.Communications biology · 2021Article
- Chemical-Genetic Interactions as a Means to Characterize Drug Synergy.Methods in molecular biology (Clifton, N.J.) · 2021Review
- From Phenotypic Hit to Chemical Probe: Chemical Biology Approaches to Elucidate Small Molecule Action in Complex Biological Systems.Molecules (Basel, Switzerland) · 2020Review
- Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia.Leukemia · 2020Article
- Kendomycin Cytotoxicity against Bacterial, Fungal, and Mammalian Cells Is Due to Cation Chelation.Journal of natural products · 2020Article
- Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy.Frontiers in pharmacology · 2020Review
- Identifying chemogenetic interactions from CRISPR screens with drugZ.Genome medicine · 2019Article
- Using BEAN-counter to quantify genetic interactions from multiplexed barcode sequencing experiments.Nature protocols · 2019Article
- Chemogenetic interactions in human cancer cells.Computational and structural biotechnology journal · 2019Review
- Predicting bioprocess targets of chemical compounds through integration of chemical-genetic and genetic interactions.PLoS computational biology · 2018Article
- Multidimensional pooled shRNA screens in human THP-1 cells identify candidate modulators of macrophage polarization.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemogenomic profiling is a powerful and unbiased approach to elucidate pharmacological targets and the mechanism of bioactive compounds. Until recently, genome-wide, high-resolution experiments of this nature have been limited to fungal systems due to lack of mammalian genome-wide deletion collections. With the example of a novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, we demonstrate that the CRISPR/Cas9 system enables the generation of transient homo- and heterozygous deletion libraries and allows for the identification of efficacy targets and pathways mediating hypersensitivity and resistance relevant to the compound mechanism of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.